​

Bristol-Myers Squibb (BMY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BMY Stock Forecast

Bristol-Myers Squibb (BMY) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $64.67, with a high of $68.00 and a low of $61.00. This represents a 31.39% increase from the last price of $49.22.

$40 $46 $52 $58 $64 $70 High: $68 Avg: $64.67 Low: $61 Last Closed Price: $49.22

BMY Stock Rating

Bristol-Myers Squibb stock's rating consensus is Hold, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (36.84%), 22 Hold (57.89%), 2 Sell (5.26%), and 0 Strong Sell (0.00%).

Hold
Total 38 0 2 22 14 Strong Sell Sell Hold Buy Strong Buy

BMY Price Target Upside V Benchmarks

TypeNameUpside
StockBristol-Myers Squibb31.39%
SectorHealthcare Stocks 30.37%
IndustryDrug Manufacturers - General Stocks30.04%

Price Target Trends

1M3M12M
# Anlaysts229
Avg Price Target$66.50$66.50$56.33
Last Closing Price$49.22$49.22$49.22
Upside/Downside35.11%35.11%14.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2533181-25
Mar, 2544171-26
Feb, 2544171-26
Jan, 2544171-26
Dec, 2444181-27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 23, 2025Akash TewariJefferies$68.00$48.5240.15%38.16%
Apr 22, 2025David AmsellemPiper Sandler$65.00$49.8230.47%32.06%
Nov 12, 2024Evan SeigermanBMO Capital$61.00$56.238.48%23.93%
Nov 01, 2024Evan David SeigermanBMO Capital$57.00$54.324.93%15.81%
Sep 23, 2024Evan David SeigermanBMO Capital$48.00$49.56-3.15%-2.48%
Jul 29, 2024Chris ShibutaniGoldman Sachs$57.00$50.5512.76%15.81%
Jul 29, 2024Carter GouldBarclays$41.00$50.45-18.73%-16.70%
Jul 12, 2024Trung HuynhUBS$43.00$40.685.70%-12.64%
May 16, 2024Steve ScalaCowen & Co.$67.00$44.1151.89%36.12%
Jan 30, 2024James ShinDeutsche Bank$55.00$49.8710.29%11.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 23, 2025JefferiesBuyBuyhold
Apr 22, 2025Piper SandlerOverweightOverweightinitialise
Nov 13, 2024DaiwaOutperformupgrade
Nov 12, 2024BMO CapitalMarket PerformMarket Performhold
Nov 12, 2024BMO CapitalOutperformOutperformhold
Nov 04, 2024Leerink PartnersMarket PerformMarket Performhold
Oct 17, 2024BernsteinMarket Performinitialise
Oct 09, 2024UBSNeutralNeutralhold
Oct 07, 2024JefferiesMarket PerformMarket Performhold
Oct 07, 2024BarclaysUnderweightUnderweighthold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.98$3.15$2.97$3.88$-4.41----
Avg Forecast$6.40$7.47$7.39$7.38$0.91$6.94$6.25$6.28$6.16
High Forecast$6.54$7.63$7.58$7.56$1.07$7.29$7.79$7.59$6.39
Low Forecast$6.27$7.32$7.13$7.17$0.84$6.44$3.12$3.73$5.97
Surprise %-162.19%-57.83%-59.81%-47.43%-584.62%----

Revenue Forecast

$41B $42B $44B $45B $47B $49B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.52B$46.38B$46.16B$45.01B$48.30B----
Avg Forecast$42.20B$46.46B$45.92B$44.71B$47.50B$46.46B$43.89B$44.24B$41.51B
High Forecast$42.90B$47.22B$46.86B$45.03B$47.73B$47.75B$43.94B$44.28B$42.71B
Low Forecast$41.55B$45.74B$44.68B$44.30B$47.42B$45.58B$43.84B$44.20B$40.55B
Surprise %0.75%-0.15%0.52%0.66%1.68%----

Net Income Forecast

$-15B $-8B $-1B $6B $13B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.99B$6.99B$6.33B$8.03B$-8.95B----
Avg Forecast$-8.69B$6.97B$6.77B$8.03B$1.99B$14.27B$9.63B$9.71B$12.80B
High Forecast$-6.27B$8.36B$8.13B$9.63B$2.23B$15.15B$16.19B$15.76B$13.28B
Low Forecast$-11.12B$5.58B$5.42B$6.42B$1.75B$13.39B$6.48B$7.75B$12.42B
Surprise %3.47%0.34%-6.56%--549.66%----

BMY Forecast FAQ

Is Bristol-Myers Squibb stock a buy?

Bristol-Myers Squibb stock has a consensus rating of Hold, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 22 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Bristol-Myers Squibb is a neutral investment for most analysts.

What is Bristol-Myers Squibb's price target?

Bristol-Myers Squibb's price target, set by 38 Wall Street analysts, averages $64.67 over the next 12 months. The price target range spans from $61 at the low end to $68 at the high end, suggesting a potential 31.39% change from the previous closing price of $49.22.

How does Bristol-Myers Squibb stock forecast compare to its benchmarks?

Bristol-Myers Squibb's stock forecast shows a 31.39% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the drug manufacturers - general stocks industry (30.04%).

What is the breakdown of analyst ratings for Bristol-Myers Squibb over the past three months?

  • April 2025: 12.00% Strong Buy, 12.00% Buy, 72.00% Hold, 4.00% Sell, 0% Strong Sell.
  • March 2025: 15.38% Strong Buy, 15.38% Buy, 65.38% Hold, 3.85% Sell, 0% Strong Sell.
  • February 2025: 15.38% Strong Buy, 15.38% Buy, 65.38% Hold, 3.85% Sell, 0% Strong Sell.

What is Bristol-Myers Squibb’s EPS forecast?

Bristol-Myers Squibb's average annual EPS forecast for its fiscal year ending in December 2025 is $6.94, marking a -257.37% decrease from the reported $-4.41 in 2024. Estimates for the following years are $6.25 in 2026, $6.28 in 2027, and $6.16 in 2028.

What is Bristol-Myers Squibb’s revenue forecast?

Bristol-Myers Squibb's average annual revenue forecast for its fiscal year ending in December 2025 is $46.46B, reflecting a -3.80% decrease from the reported $48.3B in 2024. The forecast for 2026 is $43.89B, followed by $44.24B for 2027, and $41.51B for 2028.

What is Bristol-Myers Squibb’s net income forecast?

Bristol-Myers Squibb's net income forecast for the fiscal year ending in December 2025 stands at $14.27B, representing a -259.44% decrease from the reported $-8.948B in 2024. Projections indicate $9.63B in 2026, $9.71B in 2027, and $12.8B in 2028.